Medical Breakthrough: This Company Develops Breakthrough Treatment
Tonix Pharmaceuticals Announces Promising Data for TNX-1500 in Kidney Xenotransplantation
Tonix Pharmaceuticals Announces Promising Data for TNX-1500 in Kidney Xenotransplantation
In a groundbreaking development, Tonix Pharmaceuticals announced the publication of data involving their drug candidate TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the prevention of rejection in kidney xenotransplantation in animal models1. This announcement m…